AGM
YMAB

Alpine Global Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Alpine Global Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,866
Closed -$116K – 423
2022
Q4 		$116K Buy
+23,866
New +$173K 0.04% 200

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Alpine Global Management's YMAB Position: Q1 2023 in Review

Alpine Global Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2023, closing a stake of 23,866 shares — an estimated $116K sold.

Alpine Global Management first reported a position in YMAB in Q4 2022 and held it in 1 quarter. The position peaked at $116K in Q4 2022. 85 funds tracked by Wall St. Rank hold YMAB as of Q1 2023.

  • Alpine Global Management reported no remaining Y-mAbs Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 23,866 Y-mAbs Therapeutics shares in Q1 2023, an estimated $116K.
  • Alpine Global Management first reported a position in Y-mAbs Therapeutics in Q4 2022 and held it in 1 quarter.
  • Alpine Global Management's Y-mAbs Therapeutics position peaked at $116K in Q4 2022.
  • 85 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.